Masterclass 4: A High-Titer CHO Cell-Based Integrated Platform to Accelerate Veterinary Biologics Development

A High-Titer CHO Cell-Based Integrated Platform to Accelerate Veterinary Biologics Development

Chinese Hamster Ovary (CHO) cells are the leading host system for producing recombinant therapeutic biologics. Their ability to perform complex post-translational modifications, combined with high expression capacity and scalability in suspension culture, makes them widely used for recombinant proteins, monoclonal antibodies, and vaccines. Despite their potential in veterinary medicine, broader adoption is often limited by cost-of-goods (COGs).

This presentation introduces an integrated CHO-based platform designed to support efficient development and manufacturing of veterinary biologics. The platform spans discovery, CMC development, non-clinical animal studies, and commercial-scale manufacturing, enabling a streamlined path from early research to market readiness.

An optimized CHO expression system tailored for veterinary applications has been developed. By combining proprietary high-expression vector systems with chemically defined media, monoclonal antibody titers of up to 39 g/L were achieved in a 20-day intensified fed-batch process. The platform supports the development of recombinant proteins, including growth factors and monoclonal antibodies for companion animal therapeutics.

In addition, a structure-based nanoparticle polymer antigen platform has been established for vaccine development targeting animal coronaviruses, herpesviruses, and flaviviruses, offering flexibility in antigen design and improved production efficiency.

Overall, integrating high-yield CHO expression technology with scalable manufacturing provides a practical approach to reducing COGs while maintaining product quality, supporting broader adoption of recombinant biologics in animal health.

Xiao Shen (Canton Biologics)